This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study.
Program Director, Instructor, The Colorado School of Public Health and University of Colorado Cancer Center;
Advisor, Fight Colorectal Cancer, Research and Patient Education